- Home
- HUMA vs EDIT Comparison
HUMA vs EDIT Comparison
Compare HUMA & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUMA
- EDIT
- Stock Information
- Founded
- HUMA 2004
- EDIT 2013
- Country
- HUMA United States
- EDIT United States
- Employees
- HUMA N/A
- EDIT N/A
- Industry
- HUMA Biotechnology: Pharmaceutical Preparations
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HUMA Health Care
- EDIT Health Care
- Exchange
- HUMA Nasdaq
- EDIT Nasdaq
- Market Cap
- HUMA 324.0M
- EDIT 233.3M
- IPO Year
- HUMA N/A
- EDIT 2016
- Fundamental
- Price
- HUMA $1.33
- EDIT $2.38
- Analyst Decision
- HUMA Strong Buy
- EDIT Buy
- Analyst Count
- HUMA 8
- EDIT 10
- Target Price
- HUMA $10.13
- EDIT $4.13
- AVG Volume (30 Days)
- HUMA 5.0M
- EDIT 1.9M
- Earning Date
- HUMA 11-12-2025
- EDIT 11-10-2025
- Dividend Yield
- HUMA N/A
- EDIT N/A
- EPS Growth
- HUMA N/A
- EDIT N/A
- EPS
- HUMA N/A
- EDIT N/A
- Revenue
- HUMA $1,571,000.00
- EDIT $46,383,000.00
- Revenue This Year
- HUMA N/A
- EDIT N/A
- Revenue Next Year
- HUMA $1,468.13
- EDIT N/A
- P/E Ratio
- HUMA N/A
- EDIT N/A
- Revenue Growth
- HUMA N/A
- EDIT N/A
- 52 Week Low
- HUMA $1.09
- EDIT $0.91
- 52 Week High
- HUMA $6.77
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- HUMA 46.13
- EDIT 34.09
- Support Level
- HUMA $1.09
- EDIT $2.30
- Resistance Level
- HUMA $1.26
- EDIT $2.55
- Average True Range (ATR)
- HUMA 0.11
- EDIT 0.19
- MACD
- HUMA 0.02
- EDIT -0.00
- Stochastic Oscillator
- HUMA 69.12
- EDIT 17.00
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.